Role of Brain Ang (1-7) With Combination Therapy of Aliskerin in Control of Diabetic Nephropathy

ABSTRACT

Objectives: Angiotensin (1-7) system has been recognizing as physiologically major content of the renin-angiotensin system. It exhibited that Diabetic Nephropathy (DN), which is prevalent causes of end-stage renal disease, reduces Ang (1-7) peripheral activity. RAS activity in the PNS is controlled by RAS in the brain. The goal of this research is to see whether cerebral angiotensin (1-7) has a role in chronic diabetic kidney disease in wistar rats. Methods and Materials: Single dosage of streptozotocin 35 mg/kg i.p causes Diabetes Mellitus (DM). 2 doses of aliskerin and Ang (1-7) via a various route. After that there were testing of the samples. Commercially available kits were used to determine biochemical parameters linked to DN. Results: When streptozotocin was given to diabetic rats for 10 weeks, the mice displayed higher serum creatinine, blood urea as well as protein in urine, as well as a decreased amount of serum nitrite. A 2-week course of intracerebral aliskerin (100 nmol/day) and Ang (1-7) treatment decreased such changes also elevated serum nitrite in rats with DN, but only in conjunction with Ang (1-7) (4.8 g/day) separately or in combinations. Conclusion: The findings of current research imply that brain Ang (1-7) is vital in RAS peripheral activity modulation in diabetic nephropathy, which might be attributed to Ang II peripheral activity and reduced central sympathetic outflow.

KEYWORDS

• Angiotensin (1-7)
• Diabetic nephropathy
• End-Stage Renal Disease (ESRD)
• Aliskerin
• Peripheral activity
• Renin angiotensin system

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20255883Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 59, ISSUE 2SA Qualitative Study on Lecture Capturing System in Pharmacy Education-Learners’ PerspectiveSaranraj Loganathan, Rajkumaran Soundarraj, Vishwalingam Murugan Sujetha · pp. s410–s413Original ArticleSame type: Article
• Article · VOLUME 59, ISSUE 2SFormulation and Evaluation of Simvastatin Loaded Nanostructured Lipid Carrier for Topical Drug DeliveryMadhuri Desai, Shalaka Dhanna, Sujata Jadhav, Akshada Koparde, Akansha Dashwanat, Rutuja Gharal · pp. s414–s425Original ArticleSame type: Article
• Article · VOLUME 59, ISSUE 2SOptimized Vildagliptin Microsphere Formulation and in vitro Characterization Using 23 Factorial Design AnalysisSundaramoorthi Revathi, Pavadai Anitha, Sathappan Jenifer, Sivakumar Senthil Rajan · pp. s426–s435Original ArticleSame type: Article
• Article · VOLUME 59, ISSUE 2SBilosome Nanocarriers for Enhanced Oral Bioavailability and Cardiovascular Activity of MilrinoneKiruthika Santhinathan, Susmitha Durai, Rijivana Sirajudeen, Gopinath Govindhraji, Saravanan Gopal, Gayathri Kumararaja · pp. s436–s442Original ArticleSame type: Article